Peptide Myths Debunked: Steroids, Legality, and What Doctors Actually Think
Peptide therapy gets lumped in with steroids, banned substances, and snake oil online. A Southlake doctor walks through the five most common peptide myths and what the actual evidence shows. Some skepticism is fair. A lot of it is decades out of date. Here's how to tell the difference.
By Dr. Farhan Abdullah, DO | Medical Director, Magnolia Functional Wellness | Southlake, TX
A patient sat down in my office last month, opened his phone, and showed me a Reddit thread titled "Peptides are basically baby steroids and your doctor is lying to you." He looked half-amused, half-worried. He'd been considering a course of BPC-157 for a stubborn rotator cuff strain after watching too much physical therapy go nowhere, but the internet had him second-guessing whether he was about to do something dangerous, illegal, or just plain stupid.
That conversation isn't unusual. At Magnolia Functional Wellness in Southlake, I'd estimate two-thirds of new peptide consults start with the patient apologizing for asking about something they assume must be dodgy. The myths around peptide therapy run deep, and a lot of them are repeated by physicians who haven't read a paper on the subject since residency. So let's go through the big ones honestly. Some of the skepticism is fair. Some of it is decades out of date. And some of it is just confused vocabulary.
Myth 1: Peptides Are Basically Steroids With Better PR
This is the one I hear most, and I get why. Bodybuilding forums lump peptides and anabolic steroids together because both can theoretically improve recovery and body composition, both get injected, and both live in a gray market for the people misusing them. But pharmacologically, they're entirely different categories of molecule.
Anabolic-androgenic steroids are synthetic derivatives of testosterone. They bind directly to the androgen receptor and crank up protein synthesis system-wide. That's why they cause testicular shutdown, hair loss, acne, mood instability, and lipid changes when abused. Therapeutic peptides are short chains of amino acids, usually fewer than 50 residues, that mimic or modulate signaling molecules your body already makes. They generally bind to a specific receptor for a specific purpose, then they're broken down and cleared. Insulin is a peptide. Oxytocin is a peptide. So is glucagon. Nobody calls insulin a steroid.
Where the confusion gets earned is with growth hormone secretagogues like sermorelin, ipamorelin, or CJC-1295. These do nudge your pituitary to release more growth hormone, which has anabolic effects. But they work upstream of the natural feedback loop, so your body still throttles the response. That's mechanistically very different from injecting exogenous testosterone or, worse, supraphysiologic doses of synthetic GH. The peptide is a coach. The anabolic steroid is a megaphone.
If you want concrete proof that the FDA and pharmaceutical industry don't conflate the two, look at semaglutide and tirzepatide. Both are peptide therapies. The 2021 STEP 1 trial, published in the New England Journal of Medicine by Wilding and colleagues, showed once-weekly semaglutide produced an average 14.9% body weight reduction over 68 weeks in adults with obesity, compared to 2.4% for placebo. The 2022 SURMOUNT-1 trial led by Jastreboff went further: 15 mg of tirzepatide weekly produced a 20.9% reduction. These are peptide drugs prescribed by primary care doctors all over the country. They are not, in any sense, steroids.
Myth 2: Peptides Are Illegal
This one needs unpacking because the answer is "it depends entirely on which peptide and where it came from." The blanket "peptides are illegal" claim is wrong. The "all peptides are 100% legal supplements" claim is also wrong. Reality lives in the middle, and the rules shifted notably in 2023 and 2024.
First, the boring legal scaffolding. Peptides used in FDA-approved medications, things like semaglutide, tirzepatide, oxytocin, sermorelin (which is actually FDA-approved for pediatric growth hormone deficiency), are obviously legal when prescribed appropriately. They're regulated like any other pharmaceutical. Second, peptides on the FDA's 503A bulks list can be legally compounded by a licensed compounding pharmacy for an individual patient with a valid prescription. Third, anything not on that approved list, sold as "research only" by a website that refuses to ship to a verified medical address, is operating outside federal regulation. That's where the legal risk lives.
Where it gets murky: the FDA reclassified several popular peptides in late 2023, moving compounds like BPC-157, CJC-1295, ipamorelin, and thymosin beta-4 into Category 2, which effectively restricted their availability through compounding pharmacies. That doesn't mean those peptides became "illegal" in some criminal sense. It means a licensed pharmacy in the United States can no longer compound them for you. Patients can still find them through gray-market research chemical sites, but the quality, sterility, and actual identity of those products is a coin flip.
What I tell my patients in Southlake is straightforward. If a peptide is FDA-approved or on the 503A bulks list, we can prescribe it cleanly through a compounding partner. If it's not, I'm transparent about that. I won't write for it, I won't recommend a sketchy supplier, and I'll explain what we know and don't know about the molecule. There's nothing to hide. The legal map just isn't as scary as the headlines suggest, and it's not as wide-open as the supplement bros claim either.
Myth 3: Real Doctors Think Peptides Are Snake Oil
Some real doctors do, sure. But their objection is usually narrower than the myth makes it sound. Most of my colleagues in conventional internal medicine have no problem with peptides as a class. They use them constantly. Insulin, glucagon, GLP-1 agonists, calcitonin, octreotide, desmopressin, leuprolide, the entire family of peptide hormones used in fertility care, these are all peptide therapeutics. The skepticism almost always points at a specific subset: the regenerative and longevity peptides like BPC-157, TB-500, and growth hormone secretagogues. And the skepticism there is fair, because most of the evidence in humans is preliminary.
Take BPC-157, probably the most-hyped peptide on social media. The peer-reviewed literature is real, but it's almost entirely animal data. A 2023 review by Sikiric and colleagues in Pharmaceuticals catalogs decades of preclinical work showing gastroprotective, vascular, and tendon-healing effects in rodents. That's not nothing. The mechanisms look plausible, the safety profile in animals is excellent, and the consistency across labs is unusual. But we don't have phase 3 randomized controlled trials in humans. So when an orthopedist says "there's no evidence BPC-157 works for tendon healing," what they technically mean is "there's no large-scale human RCT." That's accurate. It also doesn't mean the peptide is useless. It means the evidence rung we're standing on is lower than for an FDA-approved drug.
This is where I think functional medicine and conventional medicine talk past each other. A board-certified internist trained in evidence-based hierarchies wants Cochrane-level meta-analyses before recommending anything. A functional medicine physician trained at the Institute of Functional Medicine, where I did my certification, weighs mechanism, preclinical signal, real-world clinical experience, and patient risk tolerance into a more nuanced calculus. Neither approach is wrong. They're answering slightly different questions. The patient deserves to hear both framings honestly so they can decide what level of evidence they're comfortable with.
Myth 4: Peptides Are Brand-New and Untested
Therapeutic peptides have been in clinical use for over a century. Insulin was first injected into a human patient in 1922. Oxytocin has been used in obstetrics since the 1950s. Calcitonin, vasopressin, octreotide, all of these have decades of use behind them. The class isn't new. What's new is the rapid expansion of designer peptides aimed at specific signaling pathways, and the cultural shift that's made them visible outside academic medicine.
Roughly 80 peptide drugs are FDA-approved as of 2025, and the global pipeline includes hundreds more in clinical trials. Pharmaceutical companies are pouring research dollars into this space precisely because peptides offer something small molecules struggle with: high specificity, low off-target toxicity, and the ability to mimic natural signaling with surgical precision. Peptide drugs are arguably one of the fastest-growing categories in modern pharmacology. The "brand new" framing usually comes from the fact that compounded versions of niche peptides became widely accessible to consumers around 2020 to 2022. That's a market change, not a science change.
Where the "untested" critique has real teeth is for combinations and stacking protocols that have never been studied in any rigorous way. If a clinic tells you they're going to layer five peptides at once because "they synergize," that's not evidence-based, that's vibes. I run lean protocols at my clinic for a reason. Fewer variables make it easier to actually evaluate whether a treatment is helping you. When patients come in already on a self-prescribed cocktail of seven peptides from an overseas vendor, I usually have to walk them back to a single agent so we can figure out what's working and what's just expensive urine.
Myth 5: If Peptides Worked, Your PCP Would Already Be Using Them
This is the one that makes me sigh. Your primary care doctor is a generalist managing 30 patients a day with an average appointment of 12 minutes. They are extraordinarily good at recognizing pneumonia, titrating blood pressure medications, and screening for cancer. They are not, in most cases, deep specialists in regenerative or functional medicine, any more than they're deep specialists in interventional cardiology or pediatric oncology. The fact that something hasn't reached the standard primary care toolkit doesn't mean it doesn't work. It means it lives in a sub-specialty.
I still practice as a hospitalist alongside running Magnolia. I can tell you firsthand that a hospitalist's job is to stabilize acute illness and discharge patients safely, not to optimize their long-term hormone or recovery profile. Different goals, different tools. When my patients ask why their internist hasn't mentioned peptides, I tell them the truth: their internist probably hasn't read a paper on therapeutic peptides since GLP-1s went mainstream, and even then, they're focused on the FDA-approved indications. That's not a knock. That's the reality of how medicine subspecializes. If you want a deep dive on peptides specifically, you need someone who's spent the time on this corner of medicine.
What I Actually Tell Patients in Clinic
If you're considering peptide therapy, here's the honest version. Some peptides have rock-solid human evidence, like the GLP-1s and FDA-approved growth hormone secretagogues. Some have promising mechanisms and mostly preclinical data, like BPC-157 and TB-500. Some have decent human data in narrow indications, like PT-141 for sexual dysfunction. The right approach is matching the strength of the evidence to your goals, your risk tolerance, and your willingness to be a thoughtful patient who tracks results.
What I don't recommend is buying random vials from a website. The sourcing problem is real, the sterility problem is real, and the dosing problem is real. If you're going to do this, do it through a physician who'll order labs, monitor responses, and adjust based on data, not vibes. That's how we run our peptide therapy program at Magnolia, and frankly it's the only way I think this kind of medicine should be practiced.
The peptide myths persist because the truth is messier than a hot take. Some peptides are genuinely transformative. Some are overhyped. Some are simply too new to know. A doctor who claims certainty in either direction, total believer or total skeptic, probably hasn't read enough of the literature. The honest answer for most peptides sits somewhere uncomfortable in the middle, and I think patients deserve to hear it that way.
Your Questions Answered
Led by trained medical professionals delivering safe, effective, and scientifically backed aesthetic and wellness treatments.
What's the difference between FDA-approved peptides and research peptides?
FDA-approved peptides — like tesamorelin and bremelanotide — have completed clinical trials demonstrating safety and efficacy for specific indications, are manufactured to pharmaceutical standards, and can be legally prescribed by licensed physicians. Research peptides are compounds that haven't completed the FDA approval process. They may be scientifically interesting and are often sold as "research chemicals not for human use" — a legal designation that doesn't reflect how they're actually used. The FDA has taken specific action restricting the compounding of many popular research peptides. Dr. Abdullah guides you through these medications and discusses research peptides in consultation as an educational matter.
Is sermorelin the same as HGH?
No — and the distinction is clinically meaningful. Recombinant human growth hormone (HGH) is injected exogenously, raising GH levels directly but bypassing the body's own regulatory feedback. This suppresses natural GH production over time and carries a different risk profile including potential for unchecked IGF-1 elevation. Sermorelin stimulates your pituitary to produce its own GH through the normal feedback mechanism — producing a more physiologic pulsatile pattern that's subject to normal regulatory controls. The result is GH optimization rather than GH replacement, with a more favorable safety profile and no suppression of your body's own production.
How long does it take to see results from growth hormone peptides?
Most patients notice improved sleep quality within 2–4 weeks — often the first and most consistent effect. Energy and recovery improvements typically follow over 6–8 weeks. Body composition changes — reduction in visceral fat, improvement in lean mass — develop more gradually over 3–6 months of consistent use. IGF-1 levels are checked at 8–12 weeks to confirm the peptide is producing the expected physiologic response and to guide dose optimization.
Can I combine peptides with testosterone therapy or GLP-1 medications?
Yes, and these combinations are often clinically complementary. Testosterone and growth hormone peptides work through different pathways and their effects on body composition, energy, and recovery can be synergistic. GLP-1 medications drive fat loss through caloric restriction and metabolic effects; tesamorelin specifically targets visceral fat through GH-mediated lipolysis, making the combination particularly effective for patients with metabolic syndrome and central adiposity. Combination protocols require physician oversight to optimize dosing and monitor for interactions.
What's the difference between TRT and anabolic steroids?
Therapeutic TRT restores testosterone to physiological range — typically 700–1,000 ng/dL — using physician-prescribed testosterone for a documented deficiency. Anabolic steroid use involves supraphysiological doses, often five to ten times the therapeutic range, for performance augmentation. They're mechanistically related but legally, clinically, and physiologically different. TRT prescribed by a physician for documented hypogonadism is a legitimate medical treatment. Anabolic steroids obtained without a prescription are a controlled substance violation with a substantially different risk profile at supraphysiological doses.
Need More Information?
Our team is ready to answer your specific questions and concerns.